Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01041287 · ClinicalTrials.gov registry record · Phase 4
Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells
A Phase 4 study of Hypertension, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 96
- Enrollment target
- 1
- Study location
NCT01041287 is a Phase 4 study of Hypertension that has completed, run by Emory University. The registered enrollment target is 96 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01041287, a Phase 4 study of Hypertension, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 96 participants
- Enrollment target
- 1
- Study location
Study Summary
Hypertension, or high blood pressure, is a common disease that affects many Americans, and can lead to devastating consequences such as heart attack, stroke, and death if not treated. Nebivolol is a medication that has been recently approved by the FDA for the treatment of hypertension. Nebivolol has an unusual profile compared to other medications, in that its effects may be related to release of a substance called nitric oxide. Nitric oxide is released from the cells lining the blood vessels, and nebivolol may stimulate these cells to release more nitric oxide. Our study will investigate whether treatment with nebivolol, as compared to another medication called metoprolol, in hypertensive subjects will be more effective in protecting blood vessels against the harmful effects of high blood pressure. The mechanisms we will investigate include oxidative stress markers and circulating levels of endothelial progenitor cells.
Conditions Studied
Interventions
- DRUG Nebivolol
- DRUG Metoprolol succinate
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01041287
The ClinicalTrials.gov registry entry for NCT01041287 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Nebivolol is the first listed.
NCT01041287 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT01041287 about?
NCT01041287 is a clinical study titled "Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells". Hypertension, or high blood pressure, is a common disease that affects many Americans, and can lead to devastating consequences such as heart attack, stroke, and death if not treated. Nebivolol is a medication that has been recently approved by the FDA for the treatment of hypertension. Nebivolol ha...
What is the current status of trial NCT01041287?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2009-12. Estimated completion is 2013-12.
What conditions does trial NCT01041287 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT01041287?
The interventions under investigation include: Nebivolol (DRUG), Metoprolol succinate (DRUG).
Who is sponsoring clinical trial NCT01041287?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01041287 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.